Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Research

• Publication date

  2011-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-10-2705PMID 21324921PMCID PMC3074499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma

  2010cited by this paper
• Activation of β-Catenin by Hypoxia in Hepatocellular Carcinoma Contributes to Enhanced Metastatic Potential and Poor Prognosis

  2010cited by this paper
• Progenitor‐derived hepatocellular carcinoma model in the rat

  2010cited by this paper
• Cancer gene discovery in hepatocellular carcinoma.

  2010cited by this paper
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

  2010cited by this paper
• Subtype Classification of Hepatocellular Adenoma

  2010cited by this paper
• A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.

  2010cited by this paper
• Obesity is associated with a higher risk of clear‐cell renal cell carcinoma than with other histologies

  2010cited by this paper
• EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.

  2009cited by this paper
• Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis.

  2009cited by this paper
• Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene

  2009cited by this paper
• Genome-Wide mRNA Expression Analysis of Hepatic Adaptation to High-Fat Diets Reveals Switch from an Inflammatory to Steatotic Transcriptional Program

  2009cited by this paper
• Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.

  2009cited by this paper
• EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

  2008cited by this paper
• PTEN at the crossroad of metabolic diseases and cancer in the liver.

  2008cited by this paper
• Experimental models of hepatocellular carcinoma.

  2008cited by this paper
• The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

  2008cited by this paper
• Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology.

  2008cited by this paper
• A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver

  2008cited by this paper
• Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.

  2007cited by this paper
• Distinct pathways of genomic progression to benign and malignant tumors of the liver

  2007cited by this paper
• Body size and risk of epithelial ovarian and related cancers: A population‐based case‐control study

  2007cited by this paper
• Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

  2007cited by this paper
• Body size and risk of epithelial ovarian and related cancers.

  2007cited by this paper
• Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer

  2007cited by this paper
• Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

  2006cited by this paper
• Oncogene‐specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis

  2006influential reference
• Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.

  2006cited by this paper
• Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

  2005cited by this paper
• Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma

  2005cited by this paper
• Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma.

  2005influential reference
• Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma.

  2004cited by this paper
• Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

  2004cited by this paper
• Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling

  2004cited by this paper
• Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement.

  2003cited by this paper
• Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

  2002cited by this paper
• International Classification of Rodent Tumors. The Mouse

  2001cited by this paper
• β‐catenin mutation and overexpression in hepatocellular carcinoma

  2001cited by this paper
• beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.

  2001cited by this paper
• Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.

  2000cited by this paper
• IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.

  2000cited by this paper
• IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells1 2

  2000cited by this paper
• Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin*

  1997cited by this paper
• Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.

  1997cited by this paper

• Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

  2025cites this paper
• WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials

  2025cites this paper
• Role of the Wnt/β-catenin signaling pathway in the development of HCC

  2025cites this paper
• Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γ

  2025cites this paper
• Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

  2024cites this paper
• Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges

  2024cites this paper
• Hydrodynamic Transfection of Hepatocytes for the Study of Hepatocellular Carcinogenesis.

  2024cites this paper
• Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review

  2024cites this paper
• KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression

  2024cites this paper
• Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer

  2023influential citation
• Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression

  2023cites this paper
• Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy

  2023cites this paper
• Advances in experimental animal models of hepatocellular carcinoma

  2023cites this paper
• miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism

  2023cites this paper
• The possible role of Wnt/β‐catenin signalling in vitiligo treatment

  2023cites this paper
• Expression and Function of BMP and Activin Membrane-Bound Inhibitor (BAMBI) in Chronic Liver Diseases and Hepatocellular Carcinoma

  2023cites this paper
• Therapeutic Effect of Catgut Implantation at Acupoint in a Mouse Model of Hepatocellular Carcinoma by Suppressing Immune Escape

  2022cites this paper
• Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.

  2022cites this paper
• DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2.

  2022cites this paper
• Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis

  2022cites this paper
• Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma

  2022cites this paper
• Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.

  2022cites this paper
• Molecular mechanisms of Wnt/β-catenin activation in HCC

  2022cites this paper
• β-Catenin signaling in hepatocellular carcinoma

  2022cites this paper
• In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling

  2021cites this paper
• Deleting in vivo β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumors

  2021cites this paper
• Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

  2021cites this paper
• RASSF1A independence and early galectin‐1 upregulation in PIK3CA‐induced hepatocarcinogenesis: new therapeutic venues

  2021cites this paper
• siRNA based drug design, quality, delivery and clinical translation.

  2020cites this paper
• Study on the hepatocellular carcinoma model with metastasis

  2020cites this paper
• The Hippo effector TAZ cooperates with oncogenic β-catenin to induce hepatoblastoma development in mice and humans.

  2020cites this paper
• The Hippo effector TAZ cooperates with oncogenic β-catenin in experimental and human hepatoblastoma development

  2020cites this paper
• Oncogenic driver genes and tumor microenvironment determine the type of liver cancer

  2020cites this paper
• Promotion of growth factor signaling as a critical function of β-catenin during HCC progression

  2019cites this paper
• Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.

  2019cites this paper
• Efficient nanocarriers of siRNA therapeutics for cancer treatment.

  2019cites this paper
• Mouse Models of Hepatocellular Carcinoma

  2019cites this paper
• Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma

  2019cites this paper
• Cellular Origin of Hepatocellular Carcinoma

  2019cites this paper
• AccessReview Stemness features in liver cancer

  2019cites this paper
• Focal Adhesion Kinase and β‐Catenin Cooperate to Induce Hepatocellular Carcinoma

  2019cites this paper
• Stemness features in liver cancer

  2018influential citation
• Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery.

  2018cites this paper
• Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

  2018cites this paper
• Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs

  2018cites this paper
• Successful liver-directed gene delivery by ERCP-guided hydrodynamic injection (with videos).

  2018cites this paper
• An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma

  2018cites this paper
• Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes.

  2018cites this paper
• A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment

  2018cites this paper
• THE ROLE OF STEM CELL NICHE AND TUMOR-ASSOCIATED MACROPHAGES IN HUMAN CHOLANGIOCARCINOMA

  2017cites this paper
• Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway

  2017cites this paper
• Animal Models of Liver Cancer: Current Status and Application in Preclinical Research

  2017cites this paper
• FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice

  2017cites this paper
• Emerging Concepts Linking Obesity with the Hallmarks of Cancer.

  2017cites this paper
• Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation

  2017cites this paper
• ABL1 is Overexpressed and Activated in Hepatocellular Carcinoma

  2017cites this paper
• AMPK interacts with β-catenin in the regulation of hepatocellular carcinoma cell proliferation and survival with selenium treatment.

  2016cites this paper
• Aberrant regulation of Wnt signaling in hepatocellular carcinoma

  2016cites this paper
• Molecular Mechanisms of Hepatocellular Carcinoma

  2016cites this paper
• Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype

  2016influential citation
• Delivery strategies and potential targets for siRNA in major cancer types.

  2016cites this paper
• FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.

  2016cites this paper
• Bioluminescence imaging of hepatic nutrient fluxes

  2016cites this paper
• Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti‐cancer therapy

  2016cites this paper
• LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours

  2015cites this paper
• Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches

  2015cites this paper
• FAK Is required for c‐Met/β‐catenin‐driven hepatocarcinogenesis

  2015cites this paper
• Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus.

  2015cites this paper
• A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.

  2015influential citation
• Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

  2015cites this paper
• An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis

  2015cites this paper
• SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice

  2014cites this paper
• Targeting cancer stem cells in hepatocellular carcinoma

  2014cites this paper
• c-Myc and transforming growth factor α enhance the development of hepatic lesions due to mutant β-catenin in transgenic mice.

  2014cites this paper
• Hydrodynamic transfection for generation of novel mouse models for liver cancer research.

  2014influential citation
• Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice

  2014cites this paper
• β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma.

  2014cites this paper
• Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse

  2014cites this paper
• Pharmacological modulation of beta-catenin and its applications in cancer therapy

  2013cites this paper
• Inflammation and liver tumorigenesis

  2013cites this paper
• Animal Models to Study the Interplay Between Cancer and Obesity

  2013cites this paper
• Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.

  2013cites this paper
• Chronic inflammation, immune escape, and oncogenesis in the liver: A unique neighborhood for novel intersections

  2012cites this paper
• A Multi-Mineral Natural Product Inhibits Liver Tumor Formation in C57BL/6 Mice

  2012cites this paper
• Characterization of novel, context-dependent modulators of WNT signaling in cancer

  2012cites this paper
• Stem cells in liver diseases and cancer: Recent advances on the path to new therapies

  2012cites this paper
• the critical hurdles in cancer immunotherapy

  2012cites this paper
• Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison.

  2012cites this paper
• Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells

  2012cites this paper
• Defining the critical hurdles in cancer immunotherapy

  2011cites this paper
• Hepatic stem cells

  2000cites this paper